Tus kws kho mob
QP35-26 Intensive Residential Treatment Services (IRTS) Prior Authorization (PA) Requirements
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 27, 2026
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 4161 - 4170 ntawm 4303
Tus kws kho mob
QP34-26 Billing Changes for Opioid Treatment Programs for Minnesota Health Care Programs
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 27, 2026
Tus kws kho mob
Compounded Medications - Commercial
Formulary Exception, Coverage Exception
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Non-Preferred Drug with Continuation of Therapy - Medicaid
Kev Tso Cai Ua Ntej
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Pulmonary Arterial Hypertension - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Galafold (migalastat) - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Erythropoietins - Commercial
Kev Tso Cai Ua Ntej
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Leucovorin - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Substrate Reduction Therapy - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026
Tus kws kho mob
Cablivi (caplacixumab-yhdp) - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2026